TRACON Pharmaceuticals Announces Orphan Drug Designation For Envafolimab In Soft Tissue Sarcoma

TRACON Pharmaceuticals, Inc. announced that the FDA has granted Orphan Drug Designation to envafolimab, a novel, single-domain antibody against PD-L1, for the treatment of patients with soft tissue sarcoma following submission of an amended application that included Phase I clinical trial data from sarcoma patients treated with single agent envafolimab.